Embedded Files
Advising and coaching biotech companies in strategic questions around medical affairs, leadership, organisational excellence
Advising and coaching biotech companies in strategic questions around medical affairs, leadership, organisational excellence
Martina serves as a trusted advisor and board member to innovative biotech and healthcare companies, contributing strategic insight, leadership experience, and deep sector knowledge.
She is currently a board member at Metriopharm AG, a clinical-stage biotech company developing therapies for inflammatory and age-related diseases. In this role, Martina supports the executive team in refining development strategy, strengthening investor communications, and guiding long-term positioning.
At Eisbach Bio, a precision oncology company, Martina acts as a strategic advisor, helping shape the company’s scientific direction and growth roadmap. Her contributions focus on translating complex science into actionable business strategy, supporting leadership through key inflection points.
Her advisory work is grounded in decades of experience leading global medical and R&D functions, and she brings a unique ability to bridge science, leadership, and organizational transformation.
Metriopharm AG is a Swiss clinical-stage biotechnology company dedicated to the development of novel small-molecule therapeutics targeting inflammatory and infectious diseases. Leveraging its proprietary platform centered on the modulation of oxidative stress and immune system dysregulation, Metriopharm aims to address a broad range of chronic and acute inflammatory conditions.
Eisbach Bio is a pioneering precision oncology company focused on targeting synthetic lethality in cancer. The company develops selective allosteric drugs that disrupt molecular machines responsible for genome reorganisation—key drivers of tumour evolution and survival. By exploiting unique vulnerabilities in cancer genomes, Eisbach’s therapies aim to suppress DNA repair pathways and enhance the efficacy of existing treatments such as PARP inhibitors and chemotherapy.
Founded in 2019, Eisbach Bio combines cutting-edge science with a bold vision for precision medicine, developing first-in-class inhibitors that address genetically defined tumours through its proprietary ALLOS platform
Page updated
Google Sites
Report abuse